성공을 향한
발걸음

Presentations & Publications

Total 0

  • Nov, 2024

    MIMERET, a Novel Mitochondrial-Targeted Drug, Improves Hepatic Steatosis by Stimulating Mitochondrial Fatty Acid Beta-Oxidation to Prevent Lipid Accumulation

    AASLD 2024
  • Nov, 2024

    Vactosertib, a TGF-β signaling inhibitor, in combination with Durvalumab increased mOS in ≥2L treatment of patients with PD-L1-positive advanced NSCLC

    SITC 2024
  • Aug, 2024

    The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial

    Nature Communications
  • Jul, 2024

    Oral transforming growth factor-beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity

    Cancer Communications
  • Apr, 2024

    Novel combination therapy for treating proteasome inhibitor-resistant multiple myeloma

    AACR 2024
  • Apr, 2024

    Oral TGF-beta receptor1 inhibitor, Vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity

    AACR 2024
  • Feb, 2024

    Clinical activity of transforming growth factor-β inhibitor vactosertib in combination 3 with imatinib in desmoid tumors: a multicenter phase Ib/II study

    Clinical Cancer Research
  • Nov, 2023

    A Competitive Inhibitor of MOART Showed Potent Therapeutic Effects in a Mouse Model of Collagen-induced Arthritis

    미국류마티스학회 2023(ACR 2023)
  • Oct, 2023

    Efficacy and Safety of Vactosertib and Pembrolizumab Combination in Patients with Previously Treated Microsatellite Stable Metastatic Colorectal Cancer

    유럽종양학회(ESMO)
  • Apr, 2023

    Vactosertib combined treatment with T1-44, a PRMT5 activity inhibitor, improves the survival and inhibits tumor invasion of murine pancreatic cancer model

    American Association for Cancer Research 2023(AACR 2023)
  • Feb, 2023

    Combination treatment of T1-44, a PRMT5 inhibitor with Vactosertib, an inhibitor of TGF-β signaling, inhibits invasion and prolongs survival in a mouse model of pancreatic tumors

    Cell Death and Disease (2023)
  • Jan, 2023

    Discovery of TRD-93 as a novel DRAK2 inhibitor

    BULLETIN OF THE KOREAN CHEMICAL SOCIETY
  • Dec, 2022

    MAST4 controls cell cycle in spermatogonial stem cells

    Cell proliferation(IF : 8.755)
  • Dec, 2022

    Therapeutic Implications of TGF-β Pathway in Desmoid Tumor Based on Comprehensive Molecular Profiling and Clinicopathological Properties

    Cancers
  • Oct, 2022

    ESRP1-regulated isoform switching of LRRFIP2 determines metastasis of gastric cance

    Nature communication
  • Sep, 2022

    Phase 1b Study of Vactosertib in Combination with FOLFOX in Patients with Metastatic Pancreatic Ductal Adenocarcinoma who have Failed First-Line Gemcitabine/nab-Paclitaxel

    미국암연구학회 췌장암 특별 컨퍼런스(AACR Special Conference on Pancreatic Cancer)2022
  • Jan, 2022

    Phase 1b Study of Vactosertib in Combination with nal-IRI plus 5FU/LV in Patients with Metastatic Pancreatic Ductal Adenocarcinoma who Failed First-Line Gemcitabine/nab-Paclitaxel

    미국임상종양학회 위장관종양심포지엄(ASCO GI) 2022
  • Nov, 2021

    Tumor Microenvironment based on PD-L1 and CD8 T-cell infiltration correlated with the survival of MSS mCRC patients treated vactosertib in combination with pembrolizumab

    미국 면역항암학회(SITC) 2021
  • Nov, 2021

    Spatial analysis of tumor-infiltrating lymphocytes correlates with the response of metastatic colorectal cancer patients treated with vactosertib in combination with pembrolizumab

    미국 면역항암학회(SITC) 2021
  • Jun, 2021

    Efficacy and Safety of Vactosertib and Pembrolizumab Combination in Patients with Previously Treated Microsatellite Stable Metastatic Colorectal Cancer

    미국임상종양학회(ASCO) 2021
  • Jun, 2021

    Phase 1b trial of Vactosertib in Combination with Pomalidomide in Relapsed Multiple Myeloma: A Corticosteroid-Free Approach by Targeting TGF-β Signaling Pathway

    미국임상종양학회(ASCO) 2021
  • Apr, 2021

    BAG2 Promotes Tumorigenesis and Metastasis by Regulating the Cathepsin B Cleavage in Triple Negative Breast Cancer Cells

    미국 암학회(AACR) 2021
  • Apr, 2021

    DRAK1 suppresses inflammation induced cervical cancer progression by targeting TRAF6 protein

    미국 암학회 (AACR) 2021
  • Apr, 2021

    Beneficial effect of vactosertib combined with nal IRI5 FULV in pancreatic cancer treatment

    미국 암학회 (AACR) 2021
  • Apr, 2021

    Genomic and transcriptomic analyses of desmoid tumor reveals enrichment of transforming growth factor beta responsive signature

    미국 암학회 (AACR) 2021
  • Nov, 2020

    Vactosertib and Durvalumab as Second or Later Line Treatment for PD-L1 Positive Non-small Cell Lung Cancer: Interim Result

    미국 면역항암학회 (SITC) 2020
  • Sep, 2020

    Safety and Efficacy of Vactosertib, a TGFBR1 Kinase Inhibitor, in Combination with Paclitaxel in Patients with Metastatic Gastric Adenocarcinoma

    유럽종양학회 연례회의 (ESMO) Congress 2020
  • May, 2020

    A Phase 1 study of TGF-β inhibitor, Vactosertib, in combination with Imatinib in patients with advanced desmoid tumor (aggressive fibromatosis)

    미국임상종양학회 (ASCO) 2020
  • Nov, 2019

    Safety and Preliminary clinical activity of Vactosertib, a selective TGF-β receptor I kinase inhibitor, in combination with Durvalumab in advanced Non-small cell lung cancer patients with low PD-L1 expression

    미국면역암학회 (SITC) 2019
  • Nov, 2019

    Safety and preliminary clinical activity of Vactosertib, a selective TGF-β receptor I kinase inhibitor, in combination with Pembrolizumab in patients with metastatic colorectal or gastric cancer

    미국면역암학회 (SITC) 2019
  • Nov, 2019

    TGF-β as a promising therapeutic target for treating Osteosarcoma

    Innovation in AYA cancer
  • Jun, 2018

    TGF-β Responsive signature is associated with anti-tumor effect of Vactosertib, a potent oral TGF-β receptor type1(TGFBRI) inhibitor in patients with advanced solid tumors

    미국임상종양학회 (ASCO) 2018